EICHORPublic-registry site landscape for NCT02294357, “Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib”, a Multiple Myeloma study sponsored by Oncotherapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02294357 (registry record) |
| Study title | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib |
| Official title | A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib |
| Sponsor | Oncotherapeutics |
| Condition(s) | Multiple Myeloma |
| Phase | PHASE2 |
| Listed sites | 7 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02294357.
Eichor generates a preliminary site-risk snapshot for NCT02294357 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Multiple Myeloma trials
More from Oncotherapeutics
← Eichor home · All tracked trials · Multiple Myeloma studies · Weekly briefs
